Oracle — Shares of the software giant surged over 3% on Thursday after Baird initiated coverage with an outperform rating and a price target of $365. The firm highlighted Oracle’s robust position in the burgeoning artificial intelligence sector. The stock has experienced significant fluctuations recently as investors assessed its future prospects. For the week, shares have appreciated by 4%.
MP Materials — The rare earth materials producer saw its shares rise by 7%. BMO Capital Markets reinstated coverage with a market perform rating, dubbing MP the U.S.’s “rare earth champion” following a partnership with the Department of Defense. In related news, China announced tighter export controls on rare earth materials ahead of a potential meeting between President Donald Trump and Chinese leader Xi Jinping.
Albemarle and Lithium Americas — Shares of these lithium producers also climbed as China plans to require export licenses for certain lithium-ion batteries. Albemarle’s stock increased by 7%, while Lithium Americas saw a gain of about 3%.
Tilray Brands — The cannabis company’s shares skyrocketed by approximately 24% after it reported a fiscal first-quarter profit that exceeded expectations.
Ferrari — In contrast, the luxury carmaker’s shares plummeted by 14% after it revised its electrification targets. Ferrari now anticipates that its 2030 sports car lineup will consist of 40% internal combustion engine cars, 40% hybrids, and only 20% fully electric vehicles, a reduction from its previous goal of 40% EV sales by the decade’s end.
Delta Air Lines — Shares rose nearly 5% following the airline’s strong guidance and third-quarter results that surpassed analyst expectations. Delta reported an adjusted earnings of $1.71 per share on revenue of $15.2 billion, while analysts had anticipated a profit of $1.53 per share on revenue of $15.06 billion. United Airlines, a competitor, also saw a 3% increase in its shares in the wake of Delta’s report.
Akero Therapeutics — The biopharma company experienced a nearly 17% rally after announcing its acquisition by Novo Nordisk for $54 per share, totaling $4.7 billion in cash. Akero specializes in drugs aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), with its efruxifermin drug currently in phase 3 trials. Conversely, Novo Nordisk’s shares fell by more than 1%.
PepsiCo — The snacks and beverage titan saw its shares climb about 3% after reporting third-quarter results that exceeded analyst expectations. The company earned an adjusted $2.29 per share on revenue of $23.94 billion, surpassing the anticipated profit of $2.26 per share on revenue of $23.83 billion, according to LSEG.
Oklo — Shares gained nearly 3% after Canaccord Genuity initiated coverage of the nuclear technology company with a Buy rating, forecasting strong long-term demand for nuclear energy and positioning Oklo as a potential leader in the sector.
Azz — In contrast, the stock dropped over 3% after the provider of hot-dip galvanizing and coil coating solutions reported fiscal second-quarter earnings and revenue that fell short of expectations. Azz cited weaker demand in several end markets.
—CNBC’s Michelle Fox, Fred Imbert, Alex Harring, Sarah Min, and Liz Napolitano contributed reporting (Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here.)
